Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

<< Previous

Bullboard Posts

Next >>

Comment by Journeytcon Jul 02, 2023 4:38pm

219 Views

Post# 35524331

RE:RE:RE:RE:RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

ONC dropped a planned phase 3 CRC trial several years ago to refocus on breast cancer after release of the surprising IND213 result. So I'm sure CRC will be a great result on a smaller indication. There's also more competition in this area. Nevertheless it will be an important result building upon their story and credibility.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record